278 related articles for article (PubMed ID: 21111965)
1. Targeted therapy for melanoma: a primer.
Davies MA; Gershenwald JE
Surg Oncol Clin N Am; 2011 Jan; 20(1):165-80. PubMed ID: 21111965
[TBL] [Abstract][Full Text] [Related]
2. Recent discoveries in the genetics of melanoma and their therapeutic implications.
Marquette A; Bagot M; Bensussan A; Dumaz N
Arch Immunol Ther Exp (Warsz); 2007; 55(6):363-72. PubMed ID: 18060370
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the genome to personalize therapy for melanoma.
Davies MA; Samuels Y
Oncogene; 2010 Oct; 29(41):5545-55. PubMed ID: 20697348
[TBL] [Abstract][Full Text] [Related]
4. Principles of Targeted Therapy for Melanoma.
Sun J; Carr MJ; Khushalani NI
Surg Clin North Am; 2020 Feb; 100(1):175-188. PubMed ID: 31753111
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic approaches in Melanoma - a paradigm for personalized medicine].
Dummer R; Goldinger S; Rinderknecht J; Eggmann N; Felderer L; Braun R; French LE
Praxis (Bern 1994); 2012 Jul; 101(15):955-9. PubMed ID: 22811327
[TBL] [Abstract][Full Text] [Related]
6. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
7. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
8. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
[TBL] [Abstract][Full Text] [Related]
9. GAB2 amplifications refine molecular classification of melanoma.
Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
[TBL] [Abstract][Full Text] [Related]
10. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
Girotti MR; Saturno G; Lorigan P; Marais R
Mol Oncol; 2014 Sep; 8(6):1140-58. PubMed ID: 25178978
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
12. [Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum].
Doma V; Gulya E
Orv Hetil; 2015 Apr; 156(15):583-91. PubMed ID: 25845317
[TBL] [Abstract][Full Text] [Related]
13. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances.
Flaherty KT; Fisher DE
Clin Cancer Res; 2011 Aug; 17(15):4922-8. PubMed ID: 21670085
[TBL] [Abstract][Full Text] [Related]
14. Toward a molecular classification of melanoma.
Fecher LA; Cummings SD; Keefe MJ; Alani RM
J Clin Oncol; 2007 Apr; 25(12):1606-20. PubMed ID: 17443002
[TBL] [Abstract][Full Text] [Related]
15. Ras, Raf, and MAP kinase in melanoma.
Solus JF; Kraft S
Adv Anat Pathol; 2013 Jul; 20(4):217-26. PubMed ID: 23752084
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.
Read J
Australas J Dermatol; 2013 Aug; 54(3):163-72. PubMed ID: 23330781
[TBL] [Abstract][Full Text] [Related]
17. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
[TBL] [Abstract][Full Text] [Related]
18. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
Miller DM; Flaherty KT; Tsao H
Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
[TBL] [Abstract][Full Text] [Related]
19. Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma.
Sobrevilla-Moreno N; Rivera-Sánchez D; García-Ortega D; López-Macías D; Garcilazo-Reyes A; Álvarez-Avitia M
Oncology (Williston Park); 2021 Sep; 35(9):562-566. PubMed ID: 34529396
[No Abstract] [Full Text] [Related]
20. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
